Exosome formulation developed for choroidal neovascularisation therapy
An exosome formulation has been created to deliver vascular endothelial-growth factor (VEGF) antibodies for choroidal neovascularisation therapy in models.
List view / Grid view
An exosome formulation has been created to deliver vascular endothelial-growth factor (VEGF) antibodies for choroidal neovascularisation therapy in models.
Researchers identified a potential therapeutic involving the inhibition of PIP4K enzymes which could enable the immune system to destroy tumour cells.
Scientists have developed a “llama nanobody” that is capable of chasing out human cytomegalovirus (HCMV) so it is detected by the immune system.
A new “atlas” has been created in the US that charts how 152 different antibodies attack the SARS-CoV-2 Spike protein.
Researchers have used patient-specific tumour organoid models to improve immunotherapy treatments for appendiceal cancer.
A new computer algorithm has identified highly conserved sequences in viral proteins that could make the best drug targets for COVID-19.
Bacterial metabolites showed an increase in the cytotoxic activity in immune cells that could potentially influence efficiency of tumour therapies.
New research has shown that the protein Piezo 1 prevented Treg cells from controlling the effects of inflammation in a multiple sclerosis mouse model.
A team have developed a minimally invasive exosome spray that helped repair rat hearts after myocardial infarction.
UK researchers have created a metal-based molecule that inhibits the build-up of Alzheimer’s-associated peptide, amyloid-β, in lab tests.
14 July 2021 | By Analytik Jena
In this on-demand webinar, based on field experiences with our research partners, Analytik Jena provides an overview of application demands for a reliable sample preparation automation – from a small and easy-to-use workstation, to a fully automated integration solution by Analytik Jena.
US researchers used an AAV9 vector to edit a single base mutation in a prenatal mouse model, halting progression of Hurler syndrome.
Every manufacturing process for potential biologics begins with cell line development, whether it’s for clinical trials or a market launch.
Research by a team in Canada reveals a promising therapeutic target to counter HER2-positive breast cancer.
US researchers have developed an antisperm monoclonal antibody that could become a safe and effective birth control method.